Orphan Designation

Primary Amebic Meningoencephalitis (PAM) - Naegleria fowleri **

Naegleria fowleri (commonly referred to as the “braineating amoeba”), is a free-living microscopic
ameba. The ameba is commonly found in warm
freshwater or soil and usually enters the body through
the nose. Once the ameba enters the nose, it travels
to the brain where it causes PAM, which is usually
fatal. Impavido (Miltefosine) being added to treatment has shown
promising results.

From 2005 to 2014, 35 PAM infections have been reported in the United States. All but two of these cases were fatal - the two survivors were on miltefosine.  Access to Miletofosine in a timely manner is crucial. That is why, we, at Profounda, have made Impavido available to all hospitals at no cost to keep the drug on hand so that no patient will have to wait for the potentially life changing drug. To read more about the consignment program click here. 

Infection from Naegleria fowleri is often difficult to diagnose as early symptoms often appear to be Viral Meningitis. Therefore it is essential that doctors know immediately when patients are admitted to a hospital if the patient recently swam in warm fresh water.

Minutes count. If you suspect Pam, call NOW.

**use of Impavido with this indication is off label. Please see prescribing label for more information.

Impavido and PAM in the News:

 Impavido® (miltefosine) is an FDA-approved treatment for cutaneous,  mucosal and visceral leishmaniasis in patients 12 years of age and older. PLEASE SEE FULL PRESCRIBING INFO 

Contact Your Doctor or the CDC to Learn More about IMPAVIDO (miltefosine)

®

Impavido is a registered trademark of Knight Therapeutics Licensed exclusively to Profounda in the USA

© 2015 Profounda, Inc. 

For Emergencies
Call 911